hydroxychloroquine has been researched along with Mycoplasma dispar Infection in 1 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, FL | 1 |
| Wang, CH | 1 |
| Hung, CS | 1 |
| Su, YS | 1 |
| Lee, WS | 1 |
1 other study available for hydroxychloroquine and Mycoplasma dispar Infection
| Article | Year |
|---|---|
Co-infection with an atypical pathogen of COVID-19 in a young.
Topics: Adult; Anti-Bacterial Agents; Antiviral Agents; Azithromycin; Coinfection; COVID-19 Drug Treatment; | 2021 |